At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 300 target
Drug / intervention
influenza vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Single-Blind, Placebo-Controlled Study of Influenza Vaccine in Preventing Cardiovascular Events in Post-Myocardial Infarction Patients and in Those With Stable Angina Pectoris
Shahid Beheshti University of Medical Sciences·interventional·Posted Feb 5, 2008·Updated Jan 22, 2009
In Brief
A Phase 3 clinical trial evaluating influenza vaccine and placebo for influenza vaccine for Coronary Artery Diseases and 2 related conditions. Completed, enrolled 300 participants across 1 site.
Detailed Summary
Influenza vaccine reduces the cardiovascular events in post-myocardial infarction (MI) patients and in those with stable angina (SA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIran
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedFeb 2008
Primary CompletionSep 2008
TodayJul 2026
First PostedFeb 5, 2008
Enrollment StartJan 1, 2008
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.4 years ago
Interventions
influenza vaccinebiological
Intramuscular injection of one 0.5-mL dose of influenza vaccine
placebo for influenza vaccinebiological
Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine